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Abstract: Protein toxins, such as gelonin, are highly desirable
anti-cancer drug candidates due to their unparalleled potency
and repetitive reaction mechanism in inhibiting protein trans-
lation. However, for its potential application in cancer ther-
apy, there remains the cell membrane barrier that allows
permeation of only small molecules, which must be over-
come. To address this challenge, we conjugated gelonin with
a protein transduction domain (PTD), the TAT peptide, via
genetic recombination. The chimeric TAT–gelonin fusion pro-
tein (TAT-Gel) retained equipotent N-glycosidase activity yet
displayed greater cell uptake than unmodified recombinant
gelonin (rGel), thereby yielding a significantly augmented
cytotoxic activity. Remarkably, TAT-Gel displayed up to 177-
fold lower IC50 (avg. 54.3 nM) than rGel (avg. IC50: 3640 nM)
in tested cell lines. This enhanced cytotoxicity, however, also
raised potential toxicity concerns due to the non-selectivity of
PTD in its mediated cell transduction. To solve this problem,
we investigated the plausibility of regulating the cell trans-
duction of TAT-Gel via a reversible masking using heparin
and protamine. Here, we demonstrated, both in vitro and in
vivo, that the cell transduction of TAT-Gel can be completely
curbed with heparin and yet this heparin block can be effi-
ciently reversed by the addition of protamine. This reversible
tight regulation of the cell transduction of TAT-Gel by heparin
and protamine sheds light of possible application of TAT-Gel
in achieving a highly effective yet safe drug therapy for the
treatment of tumors. VC 2014 Wiley Periodicals, Inc. J Biomed Mater
Res Part A: 103A: 409–419, 2015.
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INTRODUCTION
Protein enzymes have been drawing signiﬁcant interest as a
new class of anti-cancer drugs.1–5 Because of superior efﬁ-
ciency and a repetitive reaction mechanism, protein drugs
can supersede the potency barrier which most of the small
molecule drugs suffer, providing the opportunity to eradi-
cate tumor at an exceedingly low bioavailable drug concen-
trations at the tumor target.1 Among those proteins,
gelonin, a 30-kDa size plant derived toxin, exempliﬁes a
class of ribosome inactivating proteins (RIP) with extreme
potency in inhibiting protein synthesis. Gelonin cleaves the
adenine group at a speciﬁc position (A-4324) in the con-
served sarcin/ricin loop of the eukaryotic 28S ribosomal
RNA, resulting in an irreversible inactivation of the ribo-
somes.6,7 The efﬁciency in ribosome inactivation by gelonin
is so high that, according to numerous literature reports,
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only a few molecules of gelonin that gained access to its
cytosolic substrate ribosomes would be sufﬁcient to kill a
tumor cell.1,8 Yet clinical application of gelonin is still lim-
ited because of its poor uptake by tumor cells.8,9
To date, various approaches have been attempted to
overcome the cell membrane barrier for gelonin. Most of
these methods were by linking gelonin to a protein or pep-
tide ligands (e.g., monoclonal antibodies [mAb], growth fac-
tors, cytokines, etc.), so that it could enter cells via the
receptor-mediated endocytosis pathway.1,10–12 The success
of such methods, however, relied heavily on the extent of
internalization of the ligand–receptor complex, which could
vary signiﬁcantly dependent upon the type of ligands and
receptors involved.12 Moreover, once endocytosed, the drugs
would be entrapped in the endosomes and, unless ﬁnding a
way to escape, they would not have access to the cell cyto-
plasm—a pre-requisite for gelonin to exert cytotoxic
effects.12,13 More critically, tumor penetration by antibody is
often quite poor, due to their large size (150 kDa) and high
binding afﬁnity to the antigens, with the latter being termed
as the binding-site barrier.14
In the past 20 years, the discovery of a group of short
basic peptides, so-called “protein transduction domains
(PTDs),” has revolutionized the way to deliver cell-
impermeable macromolecules into cells.15,16 Numerous liter-
atures reported that these PTDs, such as the TAT peptide
derived from HIV viral protein, can ferry attached cargos
(almost any type of macromolecules or nano-carriers) into
all organ/tissue types, without causing membrane perturba-
tion or damage.15,17 The PTD-mediated cell internalization
was so potent that it could not be matched by the conven-
tional receptor-mediated endocytosis method.16,18–20 Never-
theless, the lack of selectivity in cell-entry has presented a
formidable challenge to successfully apply this PTD-based
strategy, because of concerns related to drug associated tox-
icity on normal tissues.15,17
To address this selectivity issue, various prodrug-type
strategies have been attempted.15,17 As direct adsorption of
PTD to the anionic constituents of the cell surface (e.g., gly-
cosaminoglycans or phospholipids) was considered to be an
essential step for initiation of cell transduction, many of the
approaches relied on blocking this event.15,17 A simple yet
effective way to achieve this goal is by reversibly masking
the cationic PTD with anionic materials (e.g., hyaluronic
acid, glutamate oligomers, heparin, etc.).21–23 Indeed, Yang
and coworkers suggested a prodrug strategy based on the
reversible masking/demasking of PTD using clinically
approved anionic heparin and cationic protamine drugs, and
demonstrated the in vitro feasibility of this strategy in regu-
lating the cell internalization of PTD-linked asparaginase, an
approved enzyme drug for treatment of leukemia.23
In this research, we synthesized a recombinant chimeric
TAT–gelonin fusion toxin (TAT-Gel) using the genetic engi-
neering method. The functionality of TAT-Gel was assessed
in vitro using the rabbit reticulocyte lysate and cellular
assays. Furthermore, we also conducted preliminary proof-
of-concept animal studies to validate the plausibility of reg-
ulating the cell uptake event of TAT-Gel through the use of
heparin and protamine. Overall, both in vitro and in vivo
studies provided strong evidence to support our hypothesis,
that is cell transduction of TAT-Gel could be effectively
inhibited by heparin masking while protamine was able to
reverse this heparin-induced block. Results presented in
this article suggest the potential of achieving an effective
yet safe delivery of TAT-Gel for cancer therapy.
MATERIALS AND METHODS
Materials
Fluorescein isothiocyanate (FITC), rhodamine B isothiocya-
nate (TRITC), heparin sulfate, and protamine sulfate were
purchased from Sigma–Aldrich (St. Louis, MO). Isopropyl-b-
thiogalactopyranoside (IPTG), kanamycin, and carbenicillin
were purchased from Fisher Scientiﬁc (Pittsburg, PA). Esche-
richia coli cells (TOP10 and BL21star (DE3)), fetal bovine
serum albumin (FBS), PBS (pH 7.4), Dulbecco’s Modiﬁed
Eagle Medium (DMEM), Hoechst 33342, pEXP-5-NT/TOPO TA
expression kit, and AcTEVTM protease were purchased from
Invitrogen (Carlsbad, CA). DNA primers were purchased from
Integrated DNA Technologies (Coralville, IA). DNA restriction
enzymes (BamHI and XhoI) and T4 DNA ligase were pur-
chased from New England Biolabs (Ipswich, MA). Rabbit
reticulocyte lysate assay system was purchased from Prom-
ega Corporation (Madison, WI). Cell proliferation kit II (XTT)
was purchased from Roche Applied Science (Indianapolis,
IN). BCA assay kit was purchased from Bio-Rad Laboratories
(Hercules, CA). LS174T human adenocarcinoma cells, CT26
murine colon cancer cells, 9L rat glioma cells, U87 MG human
glioblastoma-astrocytoma cells, HeLa human cervical cancer
cells, PC-3 human prostate cancer cells, Madin-Darby Canine
Kidney (MDCK) cells, and 293 human embryonic kidney
(HEK) cells were purchased from American Type Culture Col-
lection (ATCC, Manassas, VA). The pET28a-Gel plasmid vector
for the expression of recombinant gelonin (rGel) was a gener-
ous gift from Dr. Wolfgang E. Trommer (University of Kaiser-
slautern, Germany).24
Plasmid construction
The plasmid (pET-TAT-Gel) for expression of chimeric TAT–
gelonin fusion protein (TAT-Gel) was prepared in two steps.
First, TAT–gelonin gene (810 bp) was constructed by PCR
with TG-forward and TG-backward primers (please refer to
the Supporting Information, Table SI), using pET-Gel vector
(pET28a-Gel) as the template. After reaction, the PCR prod-
uct was puriﬁed on 1% agarose gel and ligated into a pEXP-
5-NT/TOPO vector using the vendor’s protocol (Invitrogen,
Carlsbad, CA). Next, by three-step sequential PCR reactions
using the prepared pNT/TOPO-TAT-Gel vector as the initial
template, we engineered genes encoding TEV protease
cleavable peptide (TEVp) and 63His, as well as a BamHI
cleavage site at the 50-end of TAT–gelonin gene, and created
an XhoI cleavage site at the 30-end. The primers (pTG-for-
ward 1–3 and pTG-backward) used for these PCR reactions
are summarized in Supporting Information (Supporting
Information, Table SI). The ﬁnal PCR product (BamHI-
63His-TEVp-TAT-gelonin-XhoI) was digested (BamHI and
XhoI) and, after puriﬁcation on 1% agarose gel, ligated into
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the linearized pET21a-TRX vector (ProMab Biotechnologies,
Richmond, CA) containing a thioredoxin (TRX) gene to pro-
duce the pET-TAT-Gel. The prepared pET-TAT-Gel vector was
submitted for DNA sequencing analysis. The schematic
design of pET-TAT-Gel vector and schematic images of
recombinant gelonin toxins are shown in Figure 1(A,B),
respectively.
Expression and puriﬁcation of recombinant gelonin toxins
For expression of recombinant gelonin (rGel) and TAT-Gel,
BL21 (DE3) E. coli transformed of pET-Gel and pET-TAT-Gel
were grown at 37C in LB broth containing 50 lg/mL car-
benicillin and 80 lg/mL kanamycin, respectively. At absorb-
ance (OD600) of 0.7–1.0, isopropyl-D-thiogalactoside (IPTG)
was added to the cultures as an inducer to a ﬁnal concen-
tration of 0.5 mM. After 6 h incubation at 37C with shaking
at 250 rpm, cells were harvested by centrifugation and sus-
pended in phosphate buffer saline (20 mM PBS, 300 mM
NaCl, pH 7). The cells were then lysed by sonication (4 3
30 s, with 50% output in ice bath) and centrifuged. The
supernatants were loaded onto HisPureVR Ni-NTA resin (Bio-
Rad Laboratories, Hercules, CA) and, after wash with PBS,
rGel and thioredoxin-63His tagged TAT–gelonin (a.k.a. TRX-
TAT-Gel) were eluted with 400 mM imidazole (20 mM PBS,
300 mM NaCl, 400 mM imidazole, pH 7). For further puriﬁ-
cation of rGel, the eluent was loaded onto a cation exchange
column (HiTrap Sepharose CM-FF, GE Healthcare Bio-
Sciences, Pittsburgh, PA) connected to an HPLC (Alltech 526
HPLC pump, Deerﬁeld, IL) and the ﬁnal rGel product was
puriﬁed by salt gradient elution (0–2M NaCl at a rate of
0.02M/min, ﬂow rate: 1 mL/min). TRX-TAT-Gel was incu-
bated with TEV protease (AcTEVTM protease, Invitrogen) for
the removal of thioredoxin-63His tag, and TAT-Gel was
puriﬁed on heparin column using a salt gradient (0–1.4M
NaCl at a rate of 0.02M/min, ﬂow rate: 1 mL/min). The
puriﬁcation of rGel and TAT-Gel was monitored by SDS-
PAGE on 10% Tris–HCl gel. The purities of ﬁnal recombi-
nant gelonin toxin products were determined based on den-
sitometry analysis using ImageJ software (National
Institutes of Health, Bethesda, MD) and the production
yields were calculated by standard BCA assay.
Protein synthesis inhibition assay
Inhibition of protein translation by TAT-Gel was evaluated,
in comparison with rGel, following the procedure of Shin
et al. using a modiﬁed rabbit reticulocyte lysate assay.9
Fluorescence dye labeling
Fluorescence dye labeling of recombinant gelonin toxins
(i.e., rGel and TAT-Gel) was performed by mixing toxins (2
mg/mL in 0.1M bicarbonate buffer, pH 9.0) with ﬁvefold
molar excess of a ﬂuorescence dye (e.g., TRITC or FITC) and
incubation for 3 h at room temperature. After incubation,
the dye-labeled rGel and TAT-Gel were puriﬁed using dye
removal resins following the vendor’s protocol (Bio-Rad,
Hercules, CA).
Transduction of TAT-Gel into LS174T cells
LS174T cells were seeded onto an eight-well chambered
coverglass (Thermo Scientiﬁc, Rockford, IL) at 105 cells/
well and incubated in complete DMEM medium with 10%
FBS. When the cells were attached to the bottom of the
chambers, TRITC-labeled rGel and TAT-Gel were separately
added to the wells and incubated at 37C for 3 h in humidi-
ﬁed CO2 incubator. After incubation, the cells were rinsed
three times with heparin/PBS (10 mg/mL heparin, 20 mM
phosphate buffer, 0.15M NaCl, pH 7.4) and their nuclei were
counterstained with Hoechst 33342. Following the Hoechst
staining, the cells were washed three times with PBS and
the images of the live cells were taken by a Nikon A1R-A1
confocal laser microscope with a 603 objective (Nikon
Instruments, Melville, NY). Cell images were acquired and
analyzed using NIS-Elements Microscope Imaging software
(Nikon Instruments, Melville, NY).
Cytotoxicity assay
The cytotoxic activity of TAT-Gel was assessed with various
cancer cell lines (LS174T, CT26, 9L, U87 MG, HeLa, and
PC3) and noncancerous cell lines (MDCK and 293 HEK) by
XTT assay. Brieﬂy, cells were dispensed into 96-well plates
at a density of 5 3 103 cells per well and incubated in com-
plete DMEM medium with 10% FBS. When the cells were
bound to the bottom of the plates, rGel and TAT-Gel were
added to the wells at varying ﬁnal concentrations (10211 to
1025M) and incubated for 72 h. After incubation, the rela-
tive cell viability was determined by XTT assay following
the vendor’s protocol (Roche Applied Science, Indianapolis,
IN). The concentrations of rGel and TAT-Gel to inhibit 50%
FIGURE 1. Scheme of recombinant toxins. A: Schematic design of
pET-TAT-Gel vector. The pET-TAT-Gel vector was constructed by
inserting the full sequence of TAT–gelonin gene into a pET-21a vector
containing thioredoxin (TRX) gene. B: Schematic images of TRX-TAT-
Gel, TAT-Gel, and rGel proteins (TRX-TAT-Gel: recombinant
thioredoxin-63His tagged-TAT–gelonin fusion protein, TAT-Gel:
recombinant TAT–gelonin fusion protein, rGel: recombinant gelonin).
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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of cell proliferation (IC50) were calculated using Prism soft-
ware (Prism version 5.0, GraphPad, CA).
Binding of TAT-Gel to heparin sepharose beads and
protamine-triggered release
Heparin bead slurries (Heparin HyperDVR M, Pall Corpora-
tion, Port Washington, NY; 50% (v/v) in PBS) were dis-
pensed to eppendorf tubes (100 lL per tube), followed by
addition of 250 lL aliquots of FITC-labeled TAT-Gel (200
lg/mL in PBS). After incubation of the bead mixtures for 1
h at room temperature, the beads were centrifuged at
10,000 rpm for 5 min and supernatants were discarded.
The beads loaded with FITC-labeled TAT-Gel were then re-
dispersed in 250 lL of rat plasma and incubated up to 24 h
at 37C. At intended time points (0 h, 1 h, 4 h, 6 h, 12 h,
and 24 h), the beads (N 5 3 per time point) were washed
with PBS for three times, and the FITC-labeled TAT-Gel
remaining on the beads’ surface were eluted with 2M NaCl
solution. To test the protamine-triggered release of TAT-Gel,
100 lL of protamine solution (10 mg/mL) was added to a
group of beads loaded with FITC-labeled TAT-Gel and incu-
bated for 30 min. After incubation, the beads were washed
with PBS for three times, and the remaining FITC-labeled
TAT-Gel on the beads’ surface was eluted with 2M NaCl
solution. For the control, FITC-labeled TAT-Gel was loaded
to beads and, after PBS wash, eluted with 2M NaCl solution,
without incubation in plasma. The ﬂuorescence intensities
of the eluents were measured by a plate reader (excitation/
emission wave length: 485 nm/530 nm, BioTEKVR SynergyTM
BioTEK, Winooski, VT) and the bound fractions of FITC-
labeled TAT-Gel remaining on the heparin beads’ surface
(%) were calculated by dividing the mean ﬂuorescence
intensities by the mean ﬂuorescence intensity of the control
group. Statistical signiﬁcant differences in the bound frac-
tion of TAT-Gel among the groups were compared by one-
way ANOVA with Tukey’s multiple comparison test as the
post hoc test using Prism software (Prism version 5.0,
GraphPad, CA).
Heparin/protamine-regulated cell transduction of TAT-Gel
LS174T cells were seeded onto an eight-well chambered cov-
erglass (Thermo Scientiﬁc, Rockford, IL) at a density of 105
cells/well and incubated in complete DMEM medium with
10% FBS. When the cells were bound to the bottom of the
chambers, TRITC-labeled TAT-Gel was added to the wells
either: (1) alone, (2) with heparin (TAT-Gel/Hep), or (3) with
heparin and protamine (“TAT-Gel/Hep1Pro”), and incubated
at 37C for 3 h. The TAT-Gel/Hep complex was prepared by
mixing TRITC-labeled TAT-Gel with threefold molar excess of
heparin and incubation at 4C for 30 min. The “TAT-Gel/
Hep1Pro” treatment was by addition of protamine (threefold
molar excess to heparin) to the wells immediately after the
cells were treated with TAT-Gel/Hep. After incubation, cells
were stringently washed for three times with heparin/PBS,
followed by another wash with PBS, and the images of the
live cells were acquired by a Nikon A1R-A1 confocal laser
microscope with a 203 objective (Nikon Instruments, Mel-
ville, NY) and analyzed using NIS-Elements Microscope Imag-
ing software (Nikon Instruments, Melville, NY).
Heparin/protamine-mediated regulation on the
cytotoxicity of TAT-Gel
LS174T cells were dispensed into 96-well plates at 5 3 103
cells per well and incubated in complete DMEM medium
with 10% FBS. When the cells were bound to the bottom of
the plates, the cells were treated with either: (1) TAT-Gel,
(2) TAT-Gel/Hep, (3) “TAT-Gel/Hep1Pro,” (4) “TAT-
Gel1Pro,” or (5) protamine (a.k.a. Pro). The ﬁnal concentra-
tion of TAT-Gel used in all the groups was 100 nM. The TAT-
Gel/Hep samples were prepared by mixing TAT-Gel with
varied molar ratios of heparin (TAT-Gel:heparin 5 20:1,
10:1, 5:1, 2:1, 1:1, or 1:3) and incubation at 4C for 30 min.
The “TAT-Gel/Hep1Pro” treatment was by addition of prota-
mine to the cells pre-treated with TAT-Gel/Hep (prepared
by TAT-Gel:heparin molar ratio of 1:3) with different hepa-
rin to protamine molar ratios of 10:1, 5:1, 2:1, 1:1, or 1:3,
and the “TAT-Gel1Pro” treatment was by addition of 10
molar excess (1 lM) of protamine to the TAT-Gel-treated
cells. In case of protamine treatment, cells were incubated
with 1 lM protamine. After treatment with the test com-
pounds, the cells were incubated at 37C for 72 h and then
the relative cell viability was measured by XTT assay. Statis-
tical signiﬁcant differences in the relative cell viability of
TAT-Gel-treated group and those of other groups were com-
pared by Student’s t-test using Prism software (Prism ver-
sion 5.0, GraphPad, CA).
In vivo evaluation of heparin/protamine-mediated
regulation using LS174T xenograft tumor mouse model
Six-week-old male athymic nude mice (body weight: 23–26 g)
were purchased from Charles Rivers Laboratories (Raleigh,
NC). Three days after arrival (day 0), LS174T cells were
implanted at the left hind region of the mice legs (5 3 106
cells/mice). When the tumor size reached 100 mm3 (day 16),
the mice were randomly divided into ﬁve groups (N 5 5 per
group) and separately treated with either: (1) PBS, (2) TAT-Gel
(injected dose: 2 lg), (3) TAT-Gel/Hep (TAT-Gel 2 lg; heparin
3 lg), (4) “TAT-Gel/Hep1Pro” (TAT-Gel 2 lg; heparin 3 lg;
protamine 3 lg), or (5) protamine (a.k.a. Pro; 3 lg). The sam-
ples were administered via intra-tumor injection at days 16
and 22. The TAT-Gel/Hep complex was freshly prepared, prior
to every treatment, by mixing TAT-Gel with threefold molar
excess of heparin and incubation at 4C for 30 min. The “TAT-
Gel/Hep1Pro” treatment was by administration of protamine
(threefold molar excess to heparin) into the tumor, 5 min after
tumor injection of TAT-Gel/Hep. Tumor size was monitored
daily with a Vernier caliper and the tumor volume (mm3) was
calculated using the following formula: V 5 (w2 3 l)/2. In this
equation, w is the width and l is the length of the tumor. When
the average tumor volume of PBS-treated mice reached 2000
mm3, Statistical signiﬁcant differences in the tumor sizes
among the groups were compared by one-way ANOVA with
Tukey’s multiple comparison test as the post hoc test using
Prism software (Prism version 5.0, GraphPad, CA). All animal
experiments were conducted according to the protocols
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approved by the University of Michigan Committee on the Use
and Care of Animals (UCUCA: protocol No. 08945-3).
Statistical analysis
All data were expressed as mean 6 standard deviation.
Unless otherwise noted, statistically signiﬁcant differences
between groups were determined by Student’s t-test (Prism
version 5.0, GraphPad, San Diego, CA) and results that
yielded p value lower than 0.05 were considered statistically
signiﬁcant.
RESULTS
Expression and puriﬁcation of recombinant gelonin
toxins
Recombinant gelonin (rGel) and chimeric TAT–gelonin fusion
protein (TAT-Gel) were successfully expressed from E. coli
as soluble proteins. The rGel was completely puriﬁed by
sequential Ni-NTA metal afﬁnity and cation exchange chro-
matography; as it appeared as a single band at 31 kDa on
SDS-PAGE (data not shown). Thioredoxin-63His tagged
TAT–gelonin (a.k.a. TRX-TAT-Gel) was also successfully puri-
ﬁed on Ni-NTA metal afﬁnity resins; as evidenced by the
appearance of an intense band at 44 kDa (Lane E) on the
SDS-PAGE (Fig. 2). By incubation of TRX-TAT-Gel with TEV
protease (AcTEVTM, Carlsbad, CA), thiredoxin-63His tag was
cleaved and the TAT-Gel was acquired after heparin column
puriﬁcation using salt gradient elution. As shown in Figure
3(A), while endogenous bacterial proteins (fractions 1 and
2) were eluted at 0 and 0.1M NaCl (retention time: 20 min);
as identiﬁed by the presence of multiple bands from the
SDS-PAGE result [lanes 1 and 2; Fig. 3(B)], TAT-Gel was
eluted as a single peak (fraction 3) at 0.7M NaCl with a lon-
ger retention time of 45 min. As seen in lane 3 of Figure
3(B), this fraction 3 yielded a single band at 31 kDa, which
was consistent with the expected size of TAT-Gel. The yields
of rGel and TAT-Gel were 1 and 3 mg/L culture, respectively,
based on BCA assay. The purity of both compounds was
determined to be higher than 95%, according to results
from densitometry analysis.
Inhibition of protein synthesis by TAT-Gel
As gelonin’s N-glycosidase activity to inhibit protein synthe-
sis was essential for exerting anti-cancer activity, we exam-
ined whether it was well-reserved following the conjugation
of gelonin with TAT, using the rabbit reticulocyte lysate
assay. Both rGel and TAT-Gel yielded similar inhibitory pro-
ﬁles for the translation of luciferase (data not shown), and
their IC50 values (rGel: 20 6 12 pM vs. TAT-Gel: 15 6 4 pM,
p > 0.05 by Student’s t-test) were statistically identical;
suggesting that incorporation of TAT did not affect the
inherent activity of gelonin in the TAT-Gel conjugate.
Transduction of TAT-Gel into LS174T cells
To examine whether TAT can induce transduction of the
fused gelonin into cells, an uptake study was conducted
with LS174T cells. The confocal microscopic images of the
cells, taken after incubation with TRITC-labeled recombinant
gelonin toxins and subsequent nuclei counter-stain with
Hoechst 33342, are displayed in Figure 4. As seen, while
virtually no ﬂuorescence signal was visible from the rGel-
treated cells [Fig. 4(A)], strong ﬂuorescence intensity was
FIGURE 2. SDS-PAGE results for Ni-NTA column purification of TRX-
TAT-Gel. Lane M: markers of the protein molecular weight standard
(Mark 12TM standard, Invitrogen), Lane CL: supernatant fraction of the
cell lysate. Lane FT 1 and 2: flow through fractions 1 and 2. Lane W:
wash fraction. Lane E: elution fraction representing TRX-TAT-Gel
(TRX-TAT-Gel: recombinant thioredoxin-63His tagged-TAT–gelonin
fusion protein). [Color figure can be viewed in the online issue, which
is available at wileyonlinelibrary.com.]
FIGURE 3. Heparin column purification of TAT-Gel after cleavage of
thioredoxin-63His tag from the TRX-TAT-Gel by incubation with TEV
protease. A: Chromatogram. Using a NaCl salt gradient from 0 to
1.4M (red line), three major fractions labeled as Peaks 1–3 eluted at 0,
0.2, and 0.7M NaCl (with retention time of 2, 20, and 45 min, respec-
tively). B: SDS-PAGE results for the fractions eluted from the heparin
column. Lane M: markers of the protein molecular weight standard
(Mark 12TM standard, Invitrogen). Lanes 1, 2, and 3 represented
results from the three peak fractions (1, 2, and 3, respectively). Results
showed that TAT-Gel was eluted from the third peak at 0.7M NaCl
(TRX-TAT-Gel: recombinant thioredoxin-63His tagged-TAT–gelonin
fusion protein, TAT-Gel: recombinant TAT–gelonin fusion protein).
[Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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observed from cells incubated with TAT-Gel [Fig. 4(B)].
These results indicated that TAT indeed promoted the cellu-
lar uptake of the cell-impermeable gelonin; presumably
through its cell transduction mechanism.
Cytotoxic activity of TAT-Gel
Given the cell penetrating ability of TAT and the well-
reserved N-glycosidase activity of gelonin, we hypothesized
that TAT-Gel would yield signiﬁcantly greater cytotoxic
effects than rGel. To test this hypothesis, cell viability stud-
ies were performed on various cancer cell lines (e.g.,
LS174T, CT26, 9L, U87 MG, HeLa, and PC-3) and noncancer-
ous cell lines (e.g., MDCK and 293 HEK). As displayed in
Table I, among all the tested cell lines, while cell death was
observed from rGel-treated cells only at above micro-molar
concentrations (avg. IC50: 4110 6 734 nM), signiﬁcantly
augmented cytotoxicity (avg. IC50: 54.3 6 13.8 nM) was
observed from cells incubated with TAT-Gel. This enhanced
cytotoxic activity of TAT-Gel provided clear evidence to the
effectiveness of the TAT fusion strategy in facilitating cell
internalization of the barely permeable gelonin.
Binding of TAT-Gel to heparin sepharose beads and
protamine-triggered release
To verify the avid binding of TAT-Gel to anionic heparin via
electrostatic interaction, and its protamine-induced release,
FIGURE 4. Cell uptake study results of rGel and TAT-Gel on LS174T
cells. The cells were incubated with either TRITC-labeled (A) rGel or
(B) TAT-Gel for 3 h at 37C. After incubation, the cells were washed
for three times with 10 mg/mL heparin/PBS solution for stringent
wash, counterstained the nuclei with Hoechst 33342, and, after three
more wash with PBS, the cell images were taken by a confocal micro-
scope using TRITC (red), Hoechst (blue) channels and merged (rGel:
recombinant gelonin, TAT-Gel: recombinant TAT–gelonin fusion pro-
tein). [Color figure can be viewed in the online issue, which is avail-
able at wileyonlinelibrary.com.]




rGel TAT-Gel Fold Difference
Cancer cells LS174T 5130 6 802 29.0 6 15.0b 177
CT26 4190 6 1120 72.2 6 26.6a 58
U87 MG 3100 6 409 46 6 13.7b 67
9L 4260 6 856 57.8 6 26.3a 74
HeLa 4980 6 920 66.4 6 31.4b 75
PC-3 3330 6 761 63.4 6 25.1a 53
Non-cancer cells MDCK 3580 6 846 53 6 16.3a 68
293 HEK 4300 6 1020 46.7 6 14.0a 92
ap < 0.001.
bp < 0.0001 by Student’s t-test (rGel: recombinant gelonin, TAT-Gel: recombinant TAT–gelonin fusion protein).
cIC50 values were calculated by nonlinear regression using Prism software (GraphPad).
All experiments were performed with three different batches (N 5 3).
FIGURE 5. Binding of TAT-Gel to heparin sepharose beads and
protamine-triggered release. FITC-labeled TAT-Gel was loaded onto
heparin beads (Heparin HyperD
VR
M, Pall Corporation, Port Washing-
ton, NY; 50% (v/v) in PBS) and incubated up to 24 h at 37C in rat
plasma. At intended time points (0 h, 1 h, 4 h, 6 h, 12 h, and 24 h),
beads (N 5 3 per time point) were washed, and the bound FITC-
labeled TAT-Gel remaining on the beads’ surface were eluted with 2M
NaCl solution. Protamine-triggered release of TAT-Gel was tested by
addition of excessive protamine (1 mg) to a group of heparin beads
loaded with FITC-labeled TAT-Gel and incubation for 30 min at 37C.
The fluorescence intensities of all the eluents were measured and the
bound fraction of FITC-labeled TAT-Gel on the heparin bead (%) for
each test tube was calculated by dividing the fluorescence intensity of
the eluent by the mean fluorescence intensity of the control group’s
eluents. Statistical significant differences in the bound fractions of
TAT-Gel among the groups were compared by one-way ANOVA with
Tukey’s multiple comparison test as the post hoc test using Prism
software (GraphPad). ***p < 0.0001 (TAT-Gel: recombinant TAT–gelo-
nin fusion protein).
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FITC-labeled TAT-Gel was loaded onto heparin beads, and
the release was monitored during incubation with rat
plasma at 37C with or without the addition of protamine.
As shown in Figure 5, the majority (80%) of added TAT-Gel
were found stably binding onto surface of the heparin beads
up to 24 h. There was no statistically signiﬁcant difference
between the bound fractions of TAT-Gel between 0 h and 24
h (p > 0.05). After the addition of protamine, however, sig-
niﬁcant amount of TAT-Gel (75%) was instantly released
within a period of 30 min.
Heparin/protamine-regulated cell transduction
of TAT-Gel
As direct adsorption of TAT to the cell membranes is an
essential requisite for initiating cell transduction, we
hypothesized that cell internalization of TAT-Gel can be
effectively regulated by physically blocking/deblocking of
the TAT on TAT-Gel with heparin and protamine, respec-
tively. To test the hypothesis, we examined the cell uptake
behavior of TAT-Gel in the presence of heparin but with or
without protamine. The scheme of this heparin/protamine-
mediated regulation on TAT-Gel cell uptake and the uptake
results are shown in Figure 6(A,B), respectively. As seen,
while strong ﬂuorescence was visible in the cells incubated
with TRITC-labeled TAT-Gel, virtually no ﬂuorescence signal
was observed from cells treated with the mixture of TAT-Gel
and heparin (TAT-Gel/Hep); suggesting that TAT-mediated
cell transduction of gelonin was completely abolished due
to heparin masking of the TAT peptide. In a sharp contrast,
cells pre-treated with TAT-Gel/Hep displayed a markedly
enhanced ﬂuorescence intensity following the addition of
protamine (“TAT-Gel/Hep1Pro”); indicating that protamine
was able to lift the heparin block and subsequently resume
the cell transduction of TAT-Gel.
Heparin/protamine-mediated regulation on the
cytotoxicity of TAT-Gel
The effects of heparin/protamine regulation on the cytotox-
icity of TAT-Gel were evaluated on LS174T cells via the XTT
assay. As shown in Figure 7, while TAT-Gel yielded signiﬁ-
cant cell death (27.4% cell viability at 100 nM), cells incu-
bated with TAT-Gel/Hep complex exhibited dramatically
attenuated cytotoxicity when the molar ratio of TAT-Gel to
heparin was reduced below 10:1. Indeed, when the TAT-
Gel:heparin molar ratio reached to 5:1,virtually no cell death
(>90% of viability) was observed; suggesting that cell
transduction of TAT-Gel was completely inhibited by heparin
masking, and therefore all TAT-Gel conjugates remained out-
side the cells. Results in Figure 7 also showed that prota-
mine by itself was not toxic to cells (95% cell viability at
1 lM), nor the addition of protamine to TAT-Gel-treated
cells further enhanced the cytotoxicity by TAT-Gel (22.4% of
relative cell viability). However, when protamine was added
to cells treated with TAT-Gel/Hep (i.e., “TAT-Gel/Hep1Pro”
treatment), at a heparin:protamine molar ratio below 5:1,
the cytotoxic effects of TAT-Gel were almost fully recovered,
reﬂecting the protamine-induced reversal of heparin block,
and thus the freed TAT-Gel could internalize cells to cause
cell death.
In vivo evaluation of heparin/protamine-mediated
regulation using LS174T xenograft tumor mouse model
The in vivo feasibility of heparin/protamine-mediated regu-
lation on cell transduction of TAT-Gel was examined using
an LS174T s.c. xenograft tumor mouse model. Tumor growth
proﬁles of mice that were administered twice with different
test compounds through intra-tumor injection are shown in
Figure 8(A) and the average tumor sizes at day 38 (38 days
after tumor implantation) are displayed in Figure 8(B).
Compared with the PBS-treated control group (tumor size:
2042 6 279 mm3 at day 38), signiﬁcant inhibition on tumor
growth (78%) was observed in mice treated with TAT-Gel
(tumor size: 450 6 258 mm3 at day 38). However, there
was no statistically signiﬁcant difference between mice
treated with TAT-Gel/Hep (tumor size: 1793 6 215 mm3,
12% inhibition) and those of control; indicating the effec-
tiveness of heparin blocking on cell transduction of TAT-Gel
in vivo. In sharp contrast, while no reduction in tumor size
FIGURE 6. Heparin/protamine modulation of TAT-Gel cell transduc-
tion. A: Schematic illustration of regulating TAT-Gel cell transduction
via reversible masking and demasking of TAT on the TAT-Gel by ani-
onic heparin and cationic protamine, respectively. B: Confocal micro-
scopic images of LS174T cells treated with TAT-Gel, TAT-Gel/Hep or
“TAT-Gel/Hep1Pro.” LS174T cells were plated onto eight-well cham-
bered coverglass (Thermo Scientific, Rockford, IL) at a density of 105
cells/well and, when cells were attached to the bottom of the cham-
bers, TRITC-labeled TAT-Gel (5 lM) was added to the wells either (1)
alone, (2) with heparin (TAT-Gel/Hep), or (3) with heparin and prota-
mine (“TAT-Gel/Hep1Pro”). After 3 h incubation, cells were washed
and the live cell images were acquired by a Nikon A1R-A1 confocal
laser microscope with a 320 objective. The TAT-Gel/Hep complex
was prepared by mixing TAT-Gel with threefold molar excess of hepa-
rin and incubation at 4C for 30 min. For “TAT-Gel/Hep1Pro” treat-
ment, cells were treated with TAT-Gel/Hep (with threefold molar
excess of heparin to TAT-Gel), followed by immediate addition of
protamine (threefold molar excess against heparin) (TAT-Gel:
recombinant TAT–gelonin fusion protein). [Color figure can be viewed
in the online issue, which is available at wileyonlinelibrary.com.]
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was observed for mice treated with protamine alone (tumor
size: 1934 6 443 mm3, 5% inhibition), substantial tumor
suppression (tumor size: 668 6 419 mm3, 67% inhibition)
was observed from mice treated with “TAT-Gel/Hep1Pro.”
These results clearly demonstrated the feasibility of
protamine-induced reversal of heparin block under the in
vivo tumor environment.
DISCUSSION
Protein transduction domains (PTDs) have drawn signiﬁcant
interest as a promising tool to deliver biologically active
macromolecules into intact cells. Numerous reports have
been found in literatures that PTDs are capable of ferrying
small molecule drugs, macromolecules (protein, gene), and
even nanoparticles into almost all types of cells with such
an efﬁcient transduction mechanism that is unmatched by
any other cell internalization pathways (e.g., endocyto-
sis).15,25,26 Nevertheless, the lack of cell selectivity of PTD in
their mediated cell transduction presents a major obstacle
to their clinical applications, because of concerns of causing
drug-induced cytotoxicity on normal tissues. Thus, selec-
tively directing the cell penetrating activity of the PTDs to
only diseased cells has been an imperative challenge that
must be addressed. In this research, we explored the feasi-
bility of improving the drugability of gelonin, a highly
potent but cell-impermeable RIP toxin, by linking it to a
renowned PTD, TAT peptide. To resolve the selectivity issue,
we tested the plausibility of regulating the cell internaliza-
tion of TAT-Gel conjugate via reversible masking and
demasking of TAT using heparin and protamine,
respectively.
For the ﬁrst time, functional recombinant TAT–gelonin
chimeric fusion protein (TAT-Gel) was successfully produced
as a soluble protein from the E. coli by adopting the co-
expression strategy based on the use of thioredoxin (TRX),
a 12-kDa oxidoreductase enzyme, as a fusion partner. Dur-
ing the early stage of producing TAT-Gel from the E. coli sys-
tem, the major obstacles that we encountered were the
poor expression and insolubility of the recombinant protein,
which was presumably attributed to the unique amino acid
composition of TAT which consists of clusters of highly
basic arginine residues that are translated by one of the rar-
est codons in E. coli.27,28 Certain literatures have noted that
cationic PTDs such as low molecular weight protamine
(LMWP) and TAT are inclined to form insoluble aggregates
that deleteriously affect the expression yields of the fusion
proteins. Lee et al. reported that, by the fusion with TAT (or
LMWP), the expression yield of mutated cocaine esterase
was markedly reduced.27 Indeed, in our early attempt to
express TAT-Gel without the help of TRX, SDS-PAGE results
showed that there was virtually no apparent soluble expres-
sion (data not shown). For the improvement of both the sol-
ubility and expression yield of TAT-Gel, TRX, as a fusion
partner, possesses several important merits, such as: (1)
producing an extraordinarily high expression (40% of the
total protein) from E. coli and (2) greatly enhancing the sol-
ubility of the fused proteins during expression.29 Indeed,
the utility of this TRX strategy was demonstrated by our
previous success in expressing soluble recombinant gelonin-
LMWP chimera.9 Consistent with these early ﬁndings, by
using the TRX as the fusion partner, a reasonably high yield
(3 mg TAT-Gel/L culture) of TAT-Gel was successfully
expressed as a soluble protein from the E. coli system; as
conﬁrmed by the results from the SDS-PAGE (Fig. 2).
Our ﬁndings indicated that the intrinsic N-glycosidase
activity of gelonin was minimally affected by the incorpora-
tion of TAT; as reﬂected by the indistinctive inhibition
FIGURE 7. Heparin/protamine-mediated regulations on cytotoxicity by TAT-Gel. LS174T cells were treated with: (1) PBS, (2) protamine (a.k.a.
Pro; 1 lM), (3) TAT-Gel, (4) TAT-Gel/Hep, (5) “TAT-Gel/Hep1Pro,” or (6) “TAT-Gel1Pro,” and, after incubation at 37C for 48 h, the relative cell
viability was determined by XTT assay. The concentration of TAT-Gel was 100 nM for all the tested groups. TAT-Gel/Hep complex was prepared
by mixing TAT-Gel and heparin in varied molar ratios (20:1, 10:1, 5:1, 2:1, 1:1, and 1:3) and incubation at 4C for 30 min. For “TAT-Gel/Hep1Pro”
treatment, protamine was added to TAT-Gel/Hep pre-treated cells (TAT-Gel:heparin 5 1:3) with varied heparin:protamine molar ratios (10:1, 5:1,
2:1, 1:1, or 1:3). In case of “TAT-Gel1Pro” treatment, 10-fold molar excess of protamine (final 1 lM concentration) was added to the TAT-Gel
pre-treated cells. For all experiments, N 5 3. Statistical significant differences in the relative cell viability of TAT-Gel-treated group and those of
other groups were compared by Student’s t-test. *p < 0.01, **p < 0.001, ***p < 0.0001 (TAT-Gel: recombinant TAT–gelonin fusion protein).
[Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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proﬁles on protein synthesis between rGel and TAT-Gel
based on the rabbit reticulocyte lysate assay. Apparently, the
small size of TAT and the intrinsic stability of gelonin’s 3D
conformational structure appeared to account for this phe-
nomenon.9,24,30 Moreover, the strategic selection of the N-
terminus of gelonin for TAT incorporation might have also
played an important role on this event. It was reported that
gelonin consisted predominantly of a ﬂexible b-sheet struc-
ture at the N-terminus, while it was composed of a re-
latively rigid a-helix near the C-terminus.30 Thus, the
N-terminus of gelonin was thought to be the preferable site
for TAT gene insertion so that the intrinsic 3D conformation
of the catalytic center could be retained. Whereas no differ-
ence was observed between recombinant gelonin (rGel) and
TAT-Gel in their activities to inhibit protein synthesis in the
absence of cells, the TAT-Gel displayed signiﬁcantly
enhanced cell uptake (Fig. 4) and cell-killing ability than
rGel, when both were being confronted with the cell mem-
brane barrier. Remarkably, the IC50 values were found to be
53–177-fold lower for TAT-Gel when compared with rGel
(Table I).
Following successful synthesis and characterizations of
TAT-Gel, the next issue remained was how to direct its cyto-
toxic effects towards only the targeted tumor cells. As
revealed by the cell viability results (Table I), TAT-Gel
yielded indiscriminative cytotoxicity against all the cell lines
tested, due to the nonselective cell transduction mechanism
of TAT that was initiated by its interaction with negatively
charged cell surface glycosaminoglycans which were present
on the membranes of the vast majority of cells.23,31 Despite
continuing efforts to develop an ideal delivery strategy for
directing the PTD-linked drugs selectively to the diseased
cells,17,32 so far there has been very little success in achiev-
ing this goal. Here, we presented a new strategy by regulat-
ing the cell transduction of TAT-Gel via heparin masking and
then the reversal of the heparin block by protamine. Hepa-
rin, a clinically used polymeric drug with an exceptionally
high density of negative charges on the surface, has been
reported to bind strongly with the highly cationic PTDs
thereby neutralizing the positive charges that are essential
for PTD-mediated cell penetration.23,33–35 Hence, mediated
by this tight heparin binding to TAT, the TAT-Gel will be
deprived of the cell-penetrating ability and subsequently its
cytotoxic activity towards normal cells during targeting of
the tumor tissue. Indeed, the avid binding of heparin and
TAT-Gel was conﬁrmed by results from heparin bead bind-
ing assay (Fig. 5). As seen, via heparin binding, cell internal-
ization of TAT-Gel was almost completely prohibited; as
evidenced by in vitro cell uptake [Fig. 6(B)] and cytotoxicity
results (Fig. 7). Although heparin was able to completely
block the cell transduction of TAT-Gel, this blockade could
be readily lifted by the administration of protamine, a clini-
cal heparin antidote possessing a much stronger binding
afﬁnity to heparin than TAT. The feasibility of protamine-
triggered relief of heparin masking was conﬁrmed by results
from the heparin bead binding assay (Fig. 5). As shown,
addition of an excess amount of protamine induced a signiﬁ-
cant release (75%) of TAT-Gel within 30 min. Moreover, via
this protamine-triggered detachment of heparin, the freed
TAT-Gel could re-gain its cell penetration ability thereby
yielding its therapeutic effects toward cancer cells [Figs.
6(B) and 7].
Encouraged by the in vitro ﬁndings, the functionality of
heparin and protamine regulating cell transduction of TAT-
Gel was further evaluated in vivo using the LS174T s.c. xeno-
graft tumor mouse model. As demonstrated in Figure 8, the
intra-tumorally administered TAT-Gel/Hep complex appeared
to remain stable and undissociated under the in vivo
FIGURE 8. In vivo evaluation of heparin/protamine regulation on TAT-
Gel cell transduction using LS174T s.c. xenograft tumor mouse
model. A: Tumor growth profiles. When the average tumor size
reached 100 mm3 (at day 16; 16 days after tumor implantation at day
0), mice were divided into five groups (N 5 5), and treated twice with
PBS (circle), TAT-Gel (triangle), TAT-Gel/Hep (square), “TAT-Gel/
Hep1Pro” (diamond), or protamine (a.k.a. Pro; reverse triangle) by
intra-tumor injection at days 16 and 22. TAT-Gel/Hep complex was
prepared by mixing TAT-Gel with threefold molar excess of heparin
and incubation at 4C for 30 min. For “TAT-Gel/Hep1Pro” treatment,
administration of TAT-Gel/Hep was followed by injection of protamine
(threefold molar excess against heparin) to the tumor with 5-min
interval. Tumor sizes were measured daily since tumor implantation
(at day 0). B: Average tumor sizes at day 38 when the average tumor
volume of PBS-treated mice reached 2000 mm3. Statistical significant
differences in the tumor sizes among the groups were compared by
one-way ANOVA with Tukey’s multiple comparison test as the post
hoc test. ***p < 0.0001. (TAT-Gel: recombinant TAT–gelonin fusion
protein). [Color figure can be viewed in the online issue, which is
available at wileyonlinelibrary.com.]
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environment; as evidenced by the insigniﬁcant reduction in
tumor size of the treated animals due to the inability of the
TAT-Gel/Hep complex to internalize cells. In a sharp contrast,
animals receiving protamine after the administration of the
TAT-Gel/Hep (“TAT-Gel/Hep1Pro”) displayed a signiﬁcant
inhibition (67%) of tumor growth, conﬁrming that the later-
administered protamine was able to reverse heparin blocking
thus resuming the cell-penetration activity of TAT-Gel. Further
extensive animal studies that involve a speciﬁc antibody for
tumor targeting as well as the tail vein injection of both the
TAT-Gel/Hep complex and protamine using LS174T s.c. xeno-
graft tumor mouse model are currently in progress in our
laboratory.
CONCLUSIONS
In this research, we report the ﬁrst synthesis of soluble and
functional recombinant TAT–gelonin chimeric fusion protein
(TAT-Gel) from E. coli. Owing to its cell internalization func-
tion, the TAT-Gel conjugate appeared to be a far superior
anti-tumor agent than the native unmodiﬁed gelonin (rGel);
as evidenced by its several orders of magnitude lower IC50
than rGel. Yet the indiscriminative cytotoxicity against all
the tested cell lines raised concerns for the use of TAT-Gel
in cancer therapy, due to the strong likelihood of triggering
gelonin-induced potential toxic effects toward normal tis-
sues. To overcome this non-selectivity and safety issue, we
examined the feasibility of a new delivery strategy by regu-
lating the cell transduction function of TAT on TAT-Gel via
heparin and protmaine-mediated masking and demasking
events, respectively. Both our in vitro and in vivo results
conﬁrmed that heparin could completely inhibit cell uptake
of the TAT-Gel conjugate, while protamine could efﬁciently
reverse this heparin blockade on TAT, thereby resuming the
potent cytotoxic effects of TAT-Gel towards target cancer
cells. Overall, this study provided a proof-of-concept demon-
stration of the feasibility and utility of the proposed TAT-
aided intracellular delivery of gelonin and, virtually all pro-
tein drugs.
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